
Lodestone Biomedical LLC Profile last edited on: 10/4/2021
CAGE: 79C36
UEI: KSGGUNHRF8D5
Business Identifier: Magnetic nanoparticle imaging equipment for nanomedicine research Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Grafton
Congr. District: 02
County: Grafton
Public Profile
With the firm's focus on enabling immediate detection of treatment response in support of precision medicine across cancer therapies and emerging immunotherapies, the Lodestone effort is to improve patient outcomes by helping medical professionals make treatment decisions earlier. The judgment is that capacity to understand the individual patient's response on a cellular level xould/will guide physicians to take the best informed course of action, Management describe the firm as Accelerating Drug Discovery, identifying the firm's focus as in vivo biomarking monitoring. Lodestones biomarker monitoring technology provides signals of efficacy to guide the development of emerging immunotherapies during preclinical development.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 2 | NIH | $2,505,000 | |
Project Title: In Vivo Pharmacotyping of Combination Therapy in Primary Brain Tumors Firm Fixed Price - Pop: 09/16/2020 - 0 |
Key People / Management
Solomon Diamond -- Chief Executive Officer
Lidia Valdes -- Co-Founder & Chief Executive Officer
Christian Knopke -- Chief Operating Officer
Lidia Valdes -- Co-Founder & Chief Executive Officer
Christian Knopke -- Chief Operating Officer
Company News
There are no news available.